Arriving in the field of obesity therapy, retatrutide presents a unique approach. Different from many available medications, retatrutide works as a double agonist, at once engaging both GLP-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. The concurrent stimulation fosters several beneficial effects, includin